New research indicates that individuals who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a prominent health publication points out that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing these medications should be aware of the potential of fast rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to pre-treatment mass within about a year and a half.
Analyzing Treatments
The research, which examined 37 of studies involving thousands of participants, compared the outcomes of these new drugs with other pills.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically experience a slower weight regain—around 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts suggest the mode of action of the drugs explains the heightened regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means appetite is no longer kept in check, making binge eating much more probable."
A Chronic Disease?
Health authorities recommend the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts contend that, due to the high risk of relapse, the treatment might need to be life-long.
This view is reinforced by drug manufacturers, who state that the results "underscore the persistent nature of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the medication describe a intense resurgence of appetite.
"I experienced a switch that goes on and I was suddenly starving," said an individual.
This difficulty is worsened if users have not adopted permanent dietary or behavioural changes during therapy.
Widespread Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is higher among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while the jabs are powerful agents for shedding pounds, they are not a magic solution and lasting health benefits likely depends on combined lifestyle support.
